Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

Randomized controlled basket trials investigating drugs targeting a rare molecular alteration are challenging. Using patients as their own control overcomes some of these challenges. Growth modulation index (GMI) is the ratio of progression-free survival (PFS) on the current therapy to time to progr...

Full description

Bibliographic Details
Main Authors: Antoine Italiano, Shivani Nanda, Andrew Briggs, Jesus Garcia-Foncillas, Ulrik Lassen, Gilles Vassal, Shivaani Kummar, Cornelis M. van Tilburg, David S. Hong, Theodore W. Laetsch, Karen Keating, John A. Reeves, Marc Fellous, Barrett H. Childs, Alexander Drilon, David M. Hyman
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
growth modulation index
larotrectinib
<i>NTRK</i> gene fusion
tropomyosin receptor kinase
TRK fusion cancer
Online Access:https://www.mdpi.com/2072-6694/12/11/3246

Internet

https://www.mdpi.com/2072-6694/12/11/3246

Similar Items